Market Closed

CELC
Celcuity
$ 64.37
0.31%   Last 24H
 
Trading with leverage comes with a high risk and may not be suitable for everyone.
   
Trading with leverage comes with a high risk and may not be suitable for everyone.
Portfolio
Updated a day ago

Celcuity News

Latest Celcuity Stock News & CELC Headlines

Celcuity Announces FDA Acceptance of sNDA for REVTORPYK™ (gedatolisib) for HR+/HER2-, PIK3CA Mutant Locally Advanced or Metastatic Breast Cancer
6 days ago | globenewswire.com
Celcuity Inc. (CELC) Q3 2026 Earnings Call Transcript
6 days ago | seekingalpha.com
What Celcuity (CELC) Said on Its Q3 Earnings Call
9 days ago | marketbeat.com
Celcuity To Participate in Upcoming Investor Conferences
12 days ago | globenewswire.com
Celcuity: Stronger Clinical Evidence, Much Lower Valuation
16 days ago | seekingalpha.com
Celcuity Schedules Release of Third Quarter 2026 Financial Results and Webcast/Conference Call
17 days ago | globenewswire.com
Celcuity Presents Updated Results from the PIK3CA MT Cohort of the Phase 3 VIKTORIA-1 Study in Patients with HR+/HER2- Advanced Breast Cancer at the ESMO Congress 2026
22 days ago | globenewswire.com
Celcuity Presents Updated Data from a Phase 1b/2 Study Evaluating Gedatolisib Plus Darolutamide in Men with Metastatic Castration-Resistant Prostate Cancer at the ESMO Congress 2026
23 days ago | globenewswire.com
Celcuity Announces Multiple Presentations At The European Society For Medical Oncology (ESMO) Congress 2026
a month ago | globenewswire.com
Celcuity Appoints David Gryska To Its Board Of Directors
a month ago | globenewswire.com
Load More

Download App

Keep track of your holdings and explore over 40,000 cryptocurrencies

oinCodex Android App
CoinCodex Mobile App
Market Closed

CELC
Celcuity
$ 64.37
0.31%   Last 24H
 
Trading with leverage comes with a high risk and may not be suitable for everyone.
   
Trading with leverage comes with a high risk and may not be suitable for everyone.
Portfolio
Updated a day ago